Breztri Aerosphere (Budesonide/Glycopyr/Formoterol) Patent Expiration, LOE Window & CMS Spending

Breztri Aerosphere (Budesonide/Glycopyr/Formoterol) by AstraZeneca: FDA Orange Book LOE 2038-10-05, 0 AB generics, $1.23B 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstraZeneca
FDA Application & PathwayN212122 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2038-10-05
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.23B
2024 Medicare Part D Spend$1.13B
2024 Medicaid Spend$95.4M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.